In summary, comprehensive analysis of MSA NfL concentrations in plasma yielded robust results in a multi-site European study of MSA, and provides evidence that NfL is a biomarker of clinical severity, future clinical progression, survival and volumetric brain changes in MSA. The gene discussed is NEFL; the disease is multiple system atrophy.